Zenas BioPharma (NASDAQ:ZBIO) CEO Purchases $1,023,720.00 in Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. acquired 57,000 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were bought at an average price of $17.96 per share, for a total transaction of $1,023,720.00. Following the completion of the transaction, the chief executive officer owned 423,155 shares of the company’s stock, valued at approximately $7,599,863.80. This trade represents a 15.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Zenas BioPharma Price Performance

Shares of Zenas BioPharma stock opened at $21.01 on Friday. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -2.97 and a beta of -1.50. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. The stock has a 50 day moving average price of $29.22 and a 200-day moving average price of $25.24. Zenas BioPharma, Inc. has a one year low of $6.11 and a one year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Wall Street Zen downgraded shares of Zenas BioPharma from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Morgan Stanley downgraded Zenas BioPharma from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $37.00 to $19.00 in a research report on Monday, January 5th. Jefferies Financial Group reiterated a “buy” rating and set a $48.00 target price on shares of Zenas BioPharma in a research report on Tuesday, January 6th. Finally, Evercore ISI initiated coverage on shares of Zenas BioPharma in a report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Zenas BioPharma has a consensus rating of “Moderate Buy” and an average price target of $43.14.

Institutional Trading of Zenas BioPharma

Several institutional investors and hedge funds have recently made changes to their positions in ZBIO. Federated Hermes Inc. raised its holdings in shares of Zenas BioPharma by 60.8% in the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after purchasing an additional 703,838 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Zenas BioPharma by 41.2% during the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock valued at $89,000 after acquiring an additional 2,679 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Zenas BioPharma by 13.9% during the 2nd quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock valued at $128,000 after purchasing an additional 1,607 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Zenas BioPharma in the third quarter valued at about $30,000. Finally, Bank of America Corp DE raised its position in shares of Zenas BioPharma by 32.3% in the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock valued at $136,000 after purchasing an additional 3,412 shares during the last quarter.

Key Stories Impacting Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO Leon Moulder Jr. bought 57,000 shares (~$1.02M) at an average $17.96, increasing his stake by ~15.6% — a sizeable insider purchase that investors often view as a strong vote of confidence. Insider purchase filing
• Positive Sentiment: Analyst consensus is supportive: the stock carries a “Moderate Buy” consensus and several buy ratings/targets above current levels, which can sustain buying interest. Analyst recommendations
• Positive Sentiment: Zenas management will present at the Guggenheim Emerging Outlook: Biotech Summit (Feb 11), providing additional analyst/investor visibility and an opportunity to highlight clinical progress. Guggenheim presentation
• Neutral Sentiment: Short-term technical/market coverage (rising relative price strength and articles explaining a 10%+ intraday move) is amplifying momentum but may be transient. Momentum coverage
• Negative Sentiment: Upcoming earnings (company projected to post results soon) and a prior quarterly EPS miss (reported loss larger than estimates) create downside risk if guidance or results disappoint. Earnings risk could trigger volatility despite the insider buy. Earnings projection and risk

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.